Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)

HK40137538APending Publication Date: 2026-09-11SUVEN LIFE SCI LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026127162
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-10
Filing Date
2026-08-06
Publication Date
2026-09-11
Patent Text Reader

Abstract

The present invention relates to piperidine substituted compounds of formula (I), or isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof, as muscarinic type M4 receptor positive allosteric modulators (M4 PAM). The invention also relates to pharmaceutical compositions comprising such compounds, chemical processes for preparing such compounds and the use of such compounds in the treatment of psychiatric and / or neurological disorders.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480071530.7 (22) Application Date 2024.11.08 (30) Priority Data 202341076908 2023.11.10 IN (85) PCT International Application Entering National Phase Date 2026.05.09 (86) PCT International Application Application Data PCT / IB2024 / 061091 2024.11.08 (87) PCT International Application Publication Data WO2025 / 099660 EN 2025.05.15 (71) Applicant: Suwen Life Sciences Ltd. Address: Telangana, India (72) Inventors: R. Niroji, A.K. Sind, A.R. Muhammad, K. Boja, A. Sheikh, P. Jayarajan, V.S. Bernard, V. Justi (74) Patent Agency: Beijing Kunrui Law Firm, 11494 Patent Attorney: Chen An (51) Int.Cl. C07D 487 / 04 (2006.01) A61P 25 / 00 (2006.01) A61K 31 / 5025 (2006.01) (54) Invention Title: Piperidine-substituted Compounds as Positive Allosteric Modulators of Muscarinic M4 Receptors (M4 PAM) (57) Abstract: This invention relates to compounds as positive allosteric modulators of muscarinic M4 receptors (M4 PAM). The present invention relates to piperidine-substituted compounds of formula (I) of PAM, or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof. The present invention also relates to pharmaceutical compositions comprising such compounds, chemical methods for preparing such compounds, and the use of such compounds in the treatment of mental disorders and / or neurological disorders. Claims 8 pages, Description 61 pages, CN 122161829 A 2026.06.05 CN 1 22 16 18 29 A 1. A compound of formula (I) or its isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, wherein each may be a single bond or a double bond independently; X1, X2, X3, and X4 are independently selected from N or C; provided that when X1, X2, X3, or X4 is N, then R2, R3, R4, or R5 is absent; R1 is selected from halogen, cyano, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -C1-C4 alkoxyalkyl, -OC1-C4 alkyl, or -OC1-C4 haloalkyl; When present, R2 is selected from hydrogen, deuterium, halogen, cyano, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl or -C1-C4 alkoxyalkyl.When present, R3 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl; when present, R4 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl; when present, R5 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl. When present, R6 is selected from hydrogen, deuterium, halogen, cyano, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl; R7 is " " indicating an attachment point; R8 and R9 are independently hydrogen, halogen, cyano, -OH, -NH2, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, - OC1-C4 alkyl, -OC1-C4 haloalkyl, -OC1-C4 alkoxyalkyl, -NHC1-C4 alkyl; or alternatively, R8 and R9 together with the carbon atoms to which they are attached form a 5-8 membered heterocycle, wherein the heterocycle is optionally substituted by one to five substituents independently selected from hydrogen, oxo, deuterium, halogen, cyano, -OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl or -C1-C4 alkoxyalkyl; and m is 0, 1 or 2. 2. A compound of formula (I) according to the foregoing embodiments, or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, wherein the compound is selected from: 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-[1-(7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine-6-yl)-piperidin-4-yloxy]-benzyl nitrile; 6-[4-(2,5-difluoro-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-fluoro-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-fluoro-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 7-methyl-6-[4-(6-methyl-pyridin-3-yloxy)-piperidin-1-yl]-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-[1-(7-methyl-[1,2,4]triazolo[4,3-b]pyridazine-6-yl)-piperidin-4-yloxy]-benzylnitrile; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1 ,3-Dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-[1-(3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine-6-yl)-piperidin-4-yloxy]-benzylnitrile; Claims 2 / 8 pages 3 CN 122161829 A 6-[4-(2-methoxy-pyridin-4-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[3-fluoro-4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1 [2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine;6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-[1-(3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine-6-yl)-piperidin-4-yloxy]-benzyl nitrile; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2-methoxy-pyridin-4-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4, 3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; Claims 3 / 8 page 4 CN 122161829 A 2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-Dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-[1 [2,4]triazolo[4,3-b]pyridazine; 3-difluoromethyl-6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-[1-(3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine-6-yl)-piperidin-4-yloxy]-benzylnitrile; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-methoxymethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl- [1,2,4]triazolo[4,3-b]pyridazine;6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-3-methoxymethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Methoxymethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; Claims 4 / 8 pages 5 CN 122161829 A 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-3-methoxymethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-3-methoxymethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-3-methoxymethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-difluoromethyl-6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-difluoromethyl-6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-difluoromethyl-6-[4-(1 ,3-Dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triAzo[1,5-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1 [2,4]triazolo[1,5-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b] Pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; Claims 5 / 8 pages 6 CN 122161829 A 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2-methoxy-pyridin-4-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine;6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 3-[1-(2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine-6-yl)-piperidin-4-yloxy]-benzylnitrile; 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine ,5-b] pyridazine; 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-2,7-dimethyl-imidazo[1,5-b]pyridazine; 2-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-imidazo[1,2-b]pyridazine; 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-2,7,8-trimethyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2-fluoromethyl-7,8-dimethyl-imidazo[1,2-b]pyridazine;2-Fluoromethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 2-Fluoromethyl-6-[4-(2-methoxy-pyridin-4-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2-fluoromethyl-7-methyl-imidazo[1,2-b]pyridazine; Claims 6 / 8, page 7, CN 122161829 A 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,3 7-Trimethyl-imidazo[1,2-b]pyridazine; 2-chloro-6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 2-chloro-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine Pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,4]dioxin-6-yloxy ...oxin-1-yl]-7,8-dioxin-1-yloxy[1,4]dioxin-6-yloxy] 2-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; or 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine. 3. The compound of formula (I) according to claim 1 or claim 2, or its isotopic form, stereoisomer.4. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or claim 2, or an isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, used as a positive allosteric modulator of muscarinic M4 receptors (M4 PAM). 5. The pharmaceutical composition according to claim 4, for treating diseases or disorders mediated by muscarinic M4 receptors, wherein the disease or disorder is selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders. 6. A compound of formula (I) according to claim 1 or claim 2, or an isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, for treating diseases or disorders mediated by muscarinic M4 receptors, wherein the disease or disorder is selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders. 7. The compound of claim 6 for the stated use, wherein the mental disorder is selected from anxiety, personality disorders, depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), bipolar disorder, attention deficit / hyperactivity disorder (ADHD), psychosis, schizophrenia, substance use disorder, and other mental disorders. 8. The compound of claim 6 for the stated use, wherein the neurological disease or disorder is selected from Alzheimer's disease, Rett syndrome, Huntington's disease, vascular dementia, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). 9. The compound of claim 6 for the stated use, wherein the cognitive impairment is selected from amnesia, dementia, forgetfulness, dementia caused by Alzheimer's disease, dementia caused by HIV, dementia caused by Huntington's disease, dementia caused by Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia, senile dementia, dementia associated with Down syndrome, dementia associated with Tourette syndrome, dementia associated with postmenopausal dementia, Creutzfeldt-Jakob disease dementia, substance-induced persistent dementia, Pick's disease dementia, Huntington's disease dementia, traumatic brain injury, prions, HIV-related neurocognitive impairment, mild cognitive impairment, and any other disease with cognitive symptoms. 10. The compound of claim 7 for the stated use, wherein the schizophrenia is selected from cognitive impairment in schizophrenia, positive symptoms of schizophrenia, and / or negative symptoms of schizophrenia. 11. The compound of claim 7 for the stated use, wherein the mental disorder is selected from psychosis associated with Alzheimer's disease, psychosis associated with Parkinson's disease, psychotic depression, psychosis associated with stroke, psychosis associated with epilepsy, psychosis associated with multiple sclerosis, psychosis associated with traumatic brain injury, and substance-induced psychosis.Persistent delirium or any other disease with psychotic features. Claims 8 / 8 Page 9 CN 122161829 A Piperidine-substituted compounds as muscarinic M4 receptor positive allosteric modulators (M4 PAM) Technical Field

[0001] The present invention relates to piperidine-substituted compounds of formula (I) as muscarinic M4 receptor positive allosteric modulators (M4 PAM) or their isotopic forms, stereoisomers or pharmaceutically acceptable salts. The invention also describes methods for preparing such compounds, pharmaceutical compositions comprising such compounds and their use in the treatment of mental disorders and / or neurological disorders. Background Art

[0002] Currently, available pharmacological treatments for mental disorders and / or neurological disorders (such as schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, depression) have shown modest improvements with dose-limiting side effects that lead to non-compliance and partial response.

[0003] Targeting muscarinic acetylcholine receptors (mAChRs) is a promising approach for the treatment of mental and / or neurological disorders because it provides a new and improved pharmacological option. mAChRs are G protein-coupled receptors (GPCRs) that are widely expressed throughout the body. To date, five subtypes, designated M1 through M5, have been identified that respond to the endogenous neurotransmitter acetylcholine (ACh). They play a key role in regulating the activity of many important functions of the central and peripheral nervous systems. The M1, M3, and M5 receptor subtypes are generally coupled to the G protein Gq / G11, while the M2 and M4 receptor subtypes are primarily coupled to the Gi / G0 protein (Wess et al., 1996, Crit Rev Neurobiol.;10(1):69-99; Langmead et al., 2008, Pharmacol Ther.;117(2):232-243).

[0004] The M4 mAChR subtype has significant therapeutic implications because it is expressed in brain regions rich in dopamine and dopamine receptors, where it regulates dopaminergic neurons associated with cognition, schizophrenia, psychosis, and addiction (Kentaro et al., 2018, Chem. Pharm. Bull. 66(1), 37–44; Daniel et al., 2019, Drug Discov Today;24(12):2307–2314).

[0005] Zanomeprazole is an M1 / M4-biased mAChR agonist that has been shown to significantly reduce behavioral symptoms in Alzheimer's disease patients (Bodick et al., 1997, Arch Neurol.;54(4):465–73), but gastrointestinal side effects have led to clinical complications.High dropout rates in clinical trials. In a separate study, zenomeprazole was shown to be effective against both positive and negative symptoms of schizophrenia (Shekhar et al., 2008, Am J Psychiatry;165(8):1033-9). Zenomeprazole showed antipsychotic-like activity in various preclinical behavioral models (Mirza et al., 2003, CNS Drug Rev.;9(2):159-86). Subsequent studies showed that zenomeprazole did not have antipsychotic-like activity in M4-KO mice (Woolley et al., 2009 Eur J Pharmacol;603(1-3):147-9). There is a high degree of conservation among muscarinic receptor subtypes at their ortho-acetylcholine ligand binding sites, making it difficult to identify selective agonists of muscarinic subtypes. To avoid agonist selectivity and safety issues, alternative approaches consist of developing selective muscarinic M4 receptor PAMs that act on less conserved allosteric binding sites.

[0006] In this regard, many muscarinic M4 receptor PAMs have been described in the literature, demonstrating cognitive enhancement and antipsychotic drug-like activity. For example, VU0467154 showed antipsychotic drug-like activity in rodent assays predicting antipsychotic effects (Gould et al., 2018, Neuropharmacology;128:492-502). In addition, muscarinic M4 receptor PAMs have shown cognitive benefits in rodent learning and memory models (Bubser et al., 2014 ACS Chem, 1 / 61 pages, 10 CN 122161829 A Neurosci.;5(10):920-42).

[0007] Patent publications WO2018 / 118736, WO2018 / 002760, WO2018 / 234953, WO2021 / 099527, WO2023 / 064584, and US20180028501 disclose compounds as muscarinic M4 receptor PAMs. Although several muscarinic M4 receptor PAMs have been disclosed in the literature to date, there are no commercially available muscarinic M4 receptor PAM compounds for the treatment of M4-mediated diseases or disorders, such as schizophrenia, Alzheimer's disease, psychosis, Parkinson's disease, pain, addiction, and Huntington's disease. Therefore, there remains an unmet need for the development of novel and more effective muscarinic M4 receptor PAMs for the treatment of disorders affected by muscarinic M4 receptors.

[0008] Literature indicates that compounds acting on muscarinic M2 receptors mediate cholinergic side effects, such as bradycardia and hypotension (Grauer et al., 2020 Brain Research;1737:146814; Sundaram et al., 1989 Brain research, 477(1-2), 358-362; Mirza et al., 2003 CNS drug reviews, 9(2), 159-186). In addition, the allosteric binding pockets of M4 and M2 muscarinic acetylcholine receptors are similar, which poses a key challenge to the development of M4 PAMs with subtype selectivity for M2. Our compound exhibits minimal activity against muscarinic M2 receptors (Wood et al., 2016 ACS medicinal chemistry letters, 8(2), 233-238; Butler et al., 2024 Journal of medicinal chemistry, 67(13), 10831-10847; Croy et al., 2014 Molecular pharmacology, 86(1), 106-115).

[0009] This invention discloses novel compounds for muscarinic M4 receptors (PAMs) having the desired characteristics. The compounds of this invention possess strong affinity for muscarinic M4, selectivity relative to muscarinic subtype receptors (such as M1, M2, M3, and M5), acceptable pharmacokinetic properties, good brain penetration, receptor occupancy, and efficacy in animal models.

[0010] In a first aspect, the present invention relates to compounds of formula (I),

[0011]

[0012] or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts,

[0013] wherein,

[0014] each may be a single bond or a double bond independently;

[0015] X1, X2, X3, and X4 are independently selected from N or C; provided that when X1, X2, X3, or X4 is N, then R2, R3, R4, or R5 is absent;

[0016] R1 is selected from halogen, cyano, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -C1-C4 alkoxyalkyl, -OC1-C4 alkyl, or -OC1-C4 haloalkyl;

[0017] When present, R2 is selected from hydrogen, deuterium, halogen, cyano, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl;

[0018] When present, R3 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl; Specification 2 / 61 pages 11 CN122161829 A

[0019] When present, R4 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl or -C1-C4 alkoxyalkyl;

[0020] When present, R5 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl or -C1-C4 alkoxyalkyl;

[0021] When present, R6 is selected from hydrogen, deuterium, halogen, cyano, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3- C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl;

[0022] R7 is

[0023] " " indicates an attachment point;

[0024] X5 is N or C;

[0025] R8 and R9 are independently selected from hydrogen, halogen, cyano, -OH, -NH2, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, -OC1-C4 alkoxyalkyl, -NHC1-C4 alkyl; or alternatively, R8 R9 and the carbon atoms to which they are attached form a 5-8 membered heterocycle, wherein the heterocycle is optionally substituted by one to five substituents independently selected from hydrogen, oxo, deuterium, halogen, cyano, -OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl and -C1-C4 alkoxyalkyl; and

[0026] m is 0, 1 or 2.

[0027] In another aspect, the present invention relates to a method for preparing a compound of formula (I) or its isotopic form or stereoisomer or pharmaceutically acceptable salt thereof.

[0028] In another aspect, the present invention relates to a compound of formula (I) used as a positive allosteric modulator of muscarinic M4 receptors, or its isotopic form, stereoisomer or pharmaceutically acceptable salt thereof.

[0029] In another aspect, the present invention relates to a method for treating muscarinic M4 receptor-mediated diseases or disorders, the method comprising administering to a patient in need a therapeutically effective amount of a compound of formula (I), or an isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof.

[0030] In another aspect, the present invention relates to a pharmaceutical composition comprising a compound of formula (I), or an isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. Detailed Description

[0031] This document discloses muscarinic M4 receptors (PAM), methods for preparing such compounds, pharmaceutical compositions comprising such compounds, and methods for treating diseases or disorders mediated by muscarinic M4 receptors (such as mental disorders and / or neurological disorders).

[0032] Unless otherwise stated, the following terms used in the specification and claims have the following meanings:

[0033] The term “-C1-C4 alkyl” as used herein refers to a branched or straight-chain aliphatic hydrocarbon containing one to four carbon atoms. Examples of -C1-C4 alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl.

[0034] The term “-C1-C4 haloalkyl” as used herein refers to -C1-C4 alkyl as defined above, wherein one or more hydrogen atoms of the same or different carbon atoms are substituted with halogen atoms. Examples of -C1-C4 haloalkyl include, but are not limited to, fluoromethyl, 2-fluoroethyl, difluoromethyl, and trifluoromethyl. Specification 3 / 61 pages 12 CN 122161829 A

[0035] As used herein, the term “-C3-C7 cycloalkyl” refers to a saturated monocyclic hydrocarbon ring containing three to seven carbon atoms. Examples of -C3-C7 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

[0036] As used herein, the term “-C1-C4 alkoxyalkyl” refers to a -C1-C4 alkyl as defined above, wherein one or more hydrogen atoms having the same or different carbon atoms are substituted by an -C1-C4 alkyl group. Examples of -C1-C4 alkoxyalkyl include, but are not limited to, methoxymethyl, ethoxymethyl, propoxymethyl, and butoxymethyl.

[0037] As used herein, the term “-OC1-C4 alkyl” refers to a -C1-C4 alkyl as defined above, which is attached to a portion of the parent molecule by an oxygen atom. Examples of -OC1-C4 alkyl include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, and butoxy.

[0038] As used herein, the term “-NHC1-C4 alkyl” refers to a -C1-C4 alkyl group as defined above, which is partially attached to a parent molecule via a nitrogen atom. Examples of -NHC1-C4 alkyl groups include, but are not limited to, methylamine, ethylamine, propylamine, and butylamine.

[0039] As used herein, the term “-OC1-C4 haloalkyl” refers to a -C1-C4 haloalkyl group as defined above, which is bonded to an oxygen atom. Examples of -OC1-C4 haloalkyl groups include, but are not limited to, -OCH2F, -OCHF2, and -OCF3.

[0040] As used herein, the term “halogen” refers to fluorine, chlorine, bromine, or iodine. Preferably, the halogen is fluorine, chlorine, or bromine.

[0041] As used herein, the phrase “5-8 membered heterocycle” refers to a saturated or unsaturated ring containing 5 to 8 carbon atoms, wherein at least one carbon atom is independently substituted by a heteroatom selected from oxygen, nitrogen, or sulfur. Non-limiting examples of 5-8 membered heterocycles include1H-pyrazolyl, 1-methyl-1H-pyrazolyl, 1H-pyrroleyl, 1-methyl-1H-pyrroleyl, oxazolyl, isoxazolyl, 2-methyloxazolyl, thiazolyl, 1H-imidazolyl, 1,4-dioxalkyl, 1,3-dioxalkyl, morpholinyl, tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, and piperazineyl.

[0042] As used herein, the phrase “isotopic form” refers to a compound of formula (I) wherein one or more atoms of the compound of formula (I) are substituted with their respective isotopes. Examples of isotopes that can be incorporated into the compounds disclosed herein include, but are not limited to, isotopes of hydrogen such as 2H (deuterium or D) and 3H (tritium or T), carbon such as 11C, 13C, and 14C, nitrogen such as 13N and 15N, oxygen such as 15O, 17O, and 18O, chlorine such as 36Cl, fluorine such as 18F, iodine such as 123I, 124I, 125I, and 131I, and sulfur such as 35S. Substitution with a heavier isotope, for example, replacing one or more key carbon-hydrogen bonds with a carbon-deuterium bond, can exhibit certain therapeutic advantages resulting from a longer metabolic cycle (e.g., increased in vivo half-life or reduced dose requirement), improved safety, or greater efficacy, and may therefore be preferred in certain circumstances.

[0043] Representative examples of isotopic forms of compounds of formula (I) may include, but are not limited to, deuterated compounds of formula (I). As used herein, the term “deuterated” refers to the substitution of one or more hydrogen atoms attached to one or more carbon atoms with a deuterium atom, either by itself or when used to modify a compound or group. For example, compounds of formula (I) may, where applicable, include deuterium, deuterated alkyl, deuterated alkoxy, deuterated cycloalkyl, deuterated heterocyclic, deuterated aryl, deuterated heteroaryl, etc., in one or more of its various variables. The term “deuterated alkyl” refers to a -C1-C4 alkyl group as defined above, wherein at least one hydrogen atom bonded to a carbon atom is replaced by deuterium. That is, in a deuterated alkyl group, at least one carbon atom is bonded to deuterium. In a deuterated alkyl group, a carbon atom may be bonded to more than one deuterium atom; more than one carbon atom in an alkyl group may be bonded to deuterium. Similarly, the term “deuterated” and the terms deuterated heterocyclic, deuterated heteroaryl, deuterated cycloalkyl, deuterated aryl, and deuterated alkoxy each refer to the corresponding chemical moiety in which at least one carbon atom is bonded to deuterium.

[0044] The term “stereoisomer” as used herein refers to isomers of the compound of formula (I) whose atoms are arranged differently in space. The compounds disclosed herein may exist as single stereoisomers, racemates, and / or mixtures of enantiomers and / or diastereomers. All such pure stereoisomers, racemates, and mixtures thereof are intended to be within the scope of the invention.

[0045] The phrase “pharmaceutically acceptable salt” as used herein refers to the active compound, i.e., the compound of formula (I). (Page 4 / 61, 13 CN 122161829 A)Salts, and depending on the specific substituents found on the compounds described herein, are prepared by reacting with a suitable acid or base.

[0046] The phrase “therapeutic effective amount” as used herein refers to an amount of the compounds of the invention that (i) treats a specific disease, symptom, or disorder, (ii) eliminates one or more symptoms of a specific disease, symptom, or disorder, and / or (iii) delays the onset of one or more symptoms of a specific disease, symptom, or disorder described herein.

[0047] The phrase “M4 receptor positive allosteric modulator (PAM)” as used herein refers to a ligand that interacts with an allosteric site of the receptor to enhance the response generated by an endogenous ligand at the orosteric binding site. The compounds of the invention are allosteric modulators of the M4 muscarinic acetylcholine receptor, including both positive allosteric modulators of the M4 muscarinic acetylcholine receptor and silencing allosteric modulators of the M4 muscarinic acetylcholine receptor.

[0048] As used herein, the phrase “mental disorder” refers to an illness or disorder such as anxiety, personality disorder, depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), bipolar disorder, attention deficit / hyperactivity disorder (ADHD), schizophrenia, substance use disorder, and other mental disorders.

[0049] As used herein, the phrase “neurological disease or disorder” refers to an illness or disorder such as Alzheimer’s disease, Rett syndrome, Huntington’s disease, vascular dementia, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).

[0050] As used herein, the phrase “cognitive impairment” refers to a disease or disorder such as amnesia, dementia, forgetfulness, dementia caused by Alzheimer’s disease, dementia caused by human immunodeficiency virus (HIV) disease, dementia caused by Huntington’s disease, dementia caused by Parkinson’s disease, Lewy body dementia, vascular dementia, frontotemporal dementia (FTD), senile dementia, dementia associated with Down syndrome, dementia associated with Tourette syndrome, dementia associated with postmenopausal syndrome, Creutzfeldt-Jakob disease dementia, substance-induced persistent dementia, Pick’s disease dementia, Huntington’s disease dementia, traumatic brain injury, prions, and HIV-related neurocognitive impairment and mild cognitive impairment.

[0051] As used herein, the term “patient” refers to an animal. Preferably, the term “patient” refers to a mammal. The term mammal includes mice, rats, dogs, rabbits, pigs, monkeys, horses, guinea pigs, and humans. More preferably, a patient is a human.

[0052] Embodiments

[0053] The present invention covers, without any limitation, all compounds described by compounds of formula (I), however preferred aspects and elements of the invention are discussed below in the embodiments.

[0054] In one embodiment, the present invention relates to compounds of formula (I),

[0055]

[0056] or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts,

[0057] wherein,

[0058] Each can be a single bond or a double bond independently;

[0059] X1, X2, X3 and X4 are independently selected from N or C; provided that when X1, X2, X3 or X4 is N, then R2, R3, R4 or R5 is not present;

[0060] R1 is selected from halogen, cyano, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -C1-C4 alkoxyalkyl, -OC1-C4 alkyl or -OC1-C4 haloalkyl;

[0061] When present, R2 is selected from hydrogen, deuterium, halogen, cyano, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl or -C1-C4 alkoxyalkyl;

[0062] When present, R3 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl;

[0063] When present, R4 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl;

[0064] When present, R5 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl;

[0065] When present, R6 is selected from hydrogen, deuterium, halogen, cyano, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl;

[0066] R7 is

[0067] " " indicates an attachment point;

[0068] X5 is N or C;

[0069] R8 and R9 are independently hydrogen, halogen, cyano, -OH, -NH2, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, -OC1-C4 alkoxyalkyl, -NHC1-C4 alkyl; or alternatively, R8 and R9 together with the carbon atoms to which they are attached form a 5-8 membered heterocycle, wherein the heterocycle is optionally substituted by one to five substituents independently selected from hydrogen, oxo, deuterium, halogen, cyano, -OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, and -C1-C4 alkoxyalkyl; and

[0070] m is 0, 1, or 2.

[0071] In another embodiment, the ring

[0072] is selected from: Specification 6 / 61 page 15 CN 122161829 A

[0073]

[0074] In another embodiment, the ring is selected from: Specification 7 / 61 page 16 CN 122161829 A

[0075]

[0076] In another embodiment, the present invention relates to a method for treating or preventing diseases or disorders mediated by muscarinic M4 receptors, the method comprising administering to a patient in need a compound of formula (I),

[0077]

[0078] or its isotopic form, stereoisomer, or pharmaceutically acceptable salt,

[0079] wherein,

[0080] may each be a single bond or a double bond independently; Specification 8 / 61 page 17 CN 122161829 A

[0081] X1, X2, X3, and X4 are independently selected from N or C; provided that R2, R3, R4, or R5 is absent when X1, X2, X3, or X4 is N;

[0082] R1 is selected from halogen, cyano, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -C1-C4 alkoxyalkyl, -OC1-C4 alkyl, or -OC1-C4 haloalkyl;

[0083] When present, R2 is selected from hydrogen, deuterium, halogen, cyano, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl;

[0084] When present, R3 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl;

[0085] When present, R4 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl;

[0086] When present, R5 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl;

[0087] When present, R6 is selected from hydrogen, deuterium, halogen, cyano, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl;

[0088] R7 is

[0089] “ ” indicates an attachment point;

[0090] X5 is N or C;

[0091] R8 and R9 are independently hydrogen, halogen, cyano, -OH, -NH2, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, -OC1-C4 alkoxyalkyl, -NHC1-C4 alkyl; or alternatively, R8 and R9 together with the carbon atoms to which they are attached form a 5-8 membered heterocycle, wherein the heterocycle is optionally substituted by one to five substituents independently selected from hydrogen, oxo, deuterium, halogen, cyano, -OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl and -C1-C4 alkoxyalkyl; and

[0092] m is 0, 1 or 2.

[0093] In another embodiment, the present invention relates to compounds selected from the following formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts:

[0094] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0095] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine;

[0096] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0097] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0098] 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0099] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; Specification 9 / 61 pages 18 CN 122161829 A

[0100] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0101] 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0102] 3-[1-(7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine-6-yl)-piperidin-4-yloxy]-benzylnitrile;

[0103] 6-[4-(2,5-difluoro-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0104] 6-[4-(6-fluoro-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0105] 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0106] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0107] 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0108] 6-[4-(6-fluoro-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0109] 7-methyl-6-[4-(6-methyl-pyridin-3-yloxy)-piperidin-1-yl]-[1,2,4]triazolo[4,3-b]pyridazine;

[0110] 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0111] 3-[1-(7-methyl-[1,2,4]triazolo[4,3-b]pyridazine-6-yl)-piperidin-4-yloxy]-benzyl nitrile;

[0112] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0113] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0114] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0115] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0116] 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0117] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0118] 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0119] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0120] 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0121] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0122] 3-[1-(3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine-6-yl)-piperidin-4-yloxy]-benzylnitrile;

[0123] 6-[4-(2-methoxy-pyridin-4-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; Specification 10 / 61 pages 19 CN 122161829 A

[0124] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0125] 6-[3-fluoro-4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0126] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0127] 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0128] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0129] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0130] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7 ,8-Dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0131] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0132] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0133] 3-[1-(3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine-6-yl)-piperidin-4-yloxy]-benzylnitrile;

[0134] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0135] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0136] 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0137] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0138] 6-[4-(2-methoxy-pyridin-4-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0139] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0140] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0141] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0142] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0143] 6-[4-(2,3-dihydro-benzo[1,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; [4]Dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; Specification 11 / 61 pages 20 CN 122161829 A

[0144] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0145] 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0146] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0147] 3-difluoromethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1

[0148] 3-Difluoromethyl-6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0149] 3-Difluoromethyl-6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0150] 3-Difluoromethyl-6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0151] 3-Difluoromethyl-6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0152] 3-Difluoromethyl-6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0153] 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0154] 3-[1-(3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine-6-yl)-piperidin-4-

[0155] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0156] 3-methoxymethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0157] 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1[2,4]triazolo[4,3-b]pyridazine;

[0158] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0159] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0160] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0161] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-3-methoxymethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0162] 3-methoxymethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0163] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-3-methoxymethyl-7-methyl- Specification 12 / 61 pages 21 CN 122161829 A [1,2,4]triazolo[4,3-b]pyridazine;

[0164] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-3-methoxymethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0165] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-3-methoxymethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0166] 3-difluoromethyl-6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0167] 3-Difluoromethyl-6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0168] 3-Difluoromethyl-6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0169] 3-Difluoromethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0170] 3-Difluoromethyl-6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine;

[0171] 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0172] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0173] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0174] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0175] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0176] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0177] 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0178] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0179] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0180] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0181] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0182] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0183] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0184] (See specification page 13 / 61, 22 CN 122161829 A)6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0185] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0186] 6-[4-(2-methoxy-pyridin-4-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0187] 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0188] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0189] 3-[1-(2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine-6-yl)-piperidin-4-yloxy]-benzylnitrile;

[0190] 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0191] 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0192] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0193] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0194] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0195] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0196] 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0197] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0198] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine;

[0199] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,7-dimethyl-imidazo[1,2-b]pyridazine;

[0200] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-imidazo[1,2-b]pyridazine;

[0201] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-imidazo[1,2-b]pyridazine;

[0202] 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-2,7,8-trimethyl-imidazo[1,2-b]pyridazine;

[0203] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2-fluoromethyl-7,8-dimethyl-imidazo[1,2-b]pyridazine;

[0204] 2-fluoromethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; Instructions for Use, Page 14 / 61, 23, CN 122161829 A

[0205] 2-fluoromethyl-6-[4-(2-methoxy-pyridin-4-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine;

[0206] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2-fluoromethyl-7-methyl-imidazo[1,2-b]pyridazine;

[0207] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,3,7-trimethyl-imidazo[1,2-b]pyridazine;

[0208] 2-Chloro-6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine;

[0209] 2-Chloro-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine;

[0210] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine;

[0211] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine;

[0212] 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine;

[0213] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine;

[0214] 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine;

[0215] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine;

[0216] 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine;

[0217] 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine;

[0218] 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; or

[0219] 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine.

[0220] Experimental Procedure

[0221] The following scheme describes a general method for preparing compounds of formula (I), wherein X1, X2, X3, X4, R1, R2, R3, R4, R5, R6, R7 and m are as defined above. In addition, Z is selected from halogens, methanesulfonates, trifluoromethanesulfonates, toluenesulfonates, etc.

[0222] Scheme: Specification 15 / 61 pages 24 CN 122161829 A

[0223]

[0224] Method-I: Preparation of compounds of formula (I)

[0225] The compound of formula-I, the compound of formula-2, cesium fluoride and triethylamine are added to a solvent selected from DMF or DMSO and heated to 100ºC-120ºC for 8 to 24 h. The resulting reaction mixture was extracted with a suitable organic solvent, washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum to obtain a residue, which was purified by column chromatography to obtain the compound of formula (I).

[0226] Method-II: Preparation of the compound of formula (I)

[0227] The compound of formula-I was reacted with the compound of formula-2 in a suitable solvent selected from toluene or 1,4-dioxane at reflux temperature for 10 to 24 hours under palladium-catalyzed cross-coupling reaction using a suitable palladium metal catalyst (such as Pd2(dba)3), a phosphine ligand (such as xantphos or BINAP), and a base (such as NaOtBu, KOtBu, or Cs2CO3).h. The resulting reaction mixture was extracted with a suitable organic solvent, washed with brine, washed with Na2SO4, filtered, and concentrated under vacuum to obtain a residue, which was purified by column chromatography to obtain the compound of formula (I).

[0228] Preparation of pharmaceutically acceptable salts of the compound of formula (I)

[0229] The compound of formula (I) can optionally be converted into its pharmaceutically acceptable salt by reaction with a suitable acid or base. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art. The salt is formed with an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, or phosphoric acid) or an organic acid (e.g., oxalic acid, succinic acid, maleic acid, acetic acid, citric acid, malic acid, tartaric acid, benzoic acid, p-toluic acid, p-toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid, or naphthalenesulfonic acid).

[0230] Preparation of Stereoisomes of Compounds of Formula (I)

[0231] Stereoisomes of compounds of Formula (I) can be prepared by one or more conventional methods as presented below:

[0232] a. One or more reagents can be used in their optically active form.

[0233] b. Optically pure catalysts or chiral ligands and metal catalysts can be used in the reduction process. The metal catalyst can be rhodium, ruthenium, indium, etc. The chiral ligand can preferably be a chiral phosphine.

[0234] c. The mixture of stereoisomers can be resolved by conventional methods, such as forming diastereomeric salts with chiral acids, chiral amines, chiral amino alcohols or chiral amino acids. The resulting diastereomeric mixture can then be separated by methods such as fractional crystallization, chromatography, etc., followed by additional steps to separate the optically active product from the resolved substance salt.

[0235] d. The mixture of stereoisomers can be resolved by conventional methods, such as microbial resolution, resolution of diastereomeric salts formed with chiral acids or chiral bases. The chiral acids that can be used include tartaric acid, mandelic acid, lactic acid, camphor sulfonic acid, amino acids, etc. The chiral bases that can be used include cinchona alkaloids, strychnine, or basic amino acids (such as lysine, arginine, etc.).

[0236] In another embodiment, suitable pharmaceutically acceptable salts include acetates, hydrochlorides, hydrobroms, oxalates, fumarates, tartrates, maleates, benzoates, methanesulfonates, and succinates.

[0237] In another embodiment of the invention, a compound of formula (I), or its isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, is used as a muscarinic M4 receptor positive allosteric modulator (PAM).

[0238] In another embodiment of the invention, a compound of formula (I), or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, is used to prepare a medicament for treating or preventing diseases or disorders mediated by muscarinic M4 receptors.

[0239] In another embodiment, the present invention relates to a method for treating or preventing a muscarinic M4 receptor-mediated disease or disorder in a patient, the method comprising administering to a patient in need a therapeutically effective amount of a compound of formula (I), or an isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof.

[0240] In another embodiment, the present invention relates to a method for treating or preventing a muscarinic M4 receptor-mediated disease or disorder selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders.

[0241] In another embodiment, the present invention relates to a compound of formula (I), or an isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, for treating a disease or disorder selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders.

[0242] In another embodiment, the present invention relates to the use of a compound of formula (I), or an isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, for treating a disease or disorder selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders.

[0243] In another embodiment, the present invention relates to the use of a compound of formula (I), or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, in the preparation of a medicament for treating a disease or disorder selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders.

[0244] In some embodiments, the mental disorder is selected from anxiety, personality disorders, depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), bipolar disorder, attention deficit / hyperactivity disorder (ADHD), schizophrenia, substance use disorder, and other mental disorders.

[0245] In some embodiments, other mental disorders include psychosis associated with Alzheimer's disease, psychosis associated with Parkinson's disease, psychotic depression, psychosis associated with stroke, psychosis associated with epilepsy, psychosis associated with multiple sclerosis, psychosis associated with traumatic brain injury, substance-induced persistent delirium, or any other disease with psychotic features.

[0246] In some embodiments, the neurological disease or disorder is selected from Alzheimer's disease, Rett syndrome, Huntington's disease, vascular dementia, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

[0247] In some embodiments, the cognitive disorder is selected from amnesia, dementia, forgetfulness, dementia caused by Alzheimer's disease, dementia caused by HIV disease, dementia caused by Huntington's disease, dementia caused by Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia (FTD), senile dementia, dementia associated with Down syndrome, dementia associated with Tourette syndrome, dementia associated with postmenopausal syndrome, Creutzfeldt-Jakob disease-related dementia, substance-induced persistent dementia, Pick's disease-related dementia.Dementia, Huntington's disease dementia, traumatic brain injury, prions, HIV-related neurocognitive impairment, mild cognitive impairment, or any other disease with cognitive symptoms.

[0248] In some embodiments, the present invention relates to a method for treating or preventing a muscarinic M4 receptor-mediated disease or disorder selected from schizophrenia.

[0249] In some embodiments, treatment of schizophrenia includes treatment of cognitive impairment in schizophrenia, positive symptoms of schizophrenia, and / or negative symptoms of schizophrenia.

[0250] In some embodiments, cognitive impairment in schizophrenia includes, but is not limited to, attention and alertness, focus, executive function, processing speed, verbal learning, working memory, problem-solving, and / or social cognition. Specification 17 / 61 pages 26 CN 122161829 A

[0251] In some embodiments, positive symptoms of schizophrenia include, but are not limited to, hallucinations, delusions, conceptual confusion, agitation, grandiosity, suspicion / persecution, and hostility.

[0252] In some embodiments, negative symptoms of schizophrenia include, but are not limited to, emotional blunting, emotional withdrawal, interpersonal dysfunction, passive / apathetic social withdrawal, difficulty with abstract thinking, lack of spontaneity and fluency of conversation, and stereotyped thinking.

[0253] In another embodiment, the invention includes pharmaceutical compositions. Such pharmaceutical compositions comprise a compound of formula (I) of the invention, or its isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, presented with a pharmaceutically acceptable carrier. The carrier may be solid, liquid, or both, and may be formulated with the compound as a unit dose composition, such as pills, tablets, coated tablets, capsules, powders, granules, patches, implants, films, liquids, semi-solids, gels, aerosols, emulsions, elixirs, etc.

[0254] The compounds of the invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition suitable for such route, and at a dose effective for the intended treatment. The active compounds and compositions may be administered, for example, orally, rectally, parenterally, or topically.

[0255] The dosage of the active compound can vary depending on a variety of factors, such as the patient's age and weight, the nature and severity of the disease to be treated, and other factors. Therefore, any reference to the therapeutically effective amount of a compound of formula (I), its stereoisomers, and pharmaceutically acceptable salts refers to the foregoing factors.

[0256] The following abbreviations are used herein:

[0257] AMP: adenosine monophosphate

[0258] BINAP: 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl

[0259] CDCl3: deuterated chloroform

[0260] Cs2CO3: cesium carbonate

[0261] DCM: dichloromethane

[0262] DIAD: diisopropyl azodicarbonate

[0263] DMA.DMA: N,N-dimethylacetamide dimethyl acetal

[0264] DMF.DMA: N,N-dimethylformamide dimethyl acetal

[0265] DMAP: 4-(dimethylamino)pyridine

[0266] DMF: N,N-dimethylformamide

[0267] DMSO: dimethyl sulfoxide

[0268] EC50: half-maximum effective concentration

[0269] EtOAc: ethyl acetate

[0270] g: gram

[0271] h: hour

[0272] hM4 PAM: human muscarinic M4 positive allosteric modifier

[0273] IPA: isopropanol

[0274] KOtBu: potassium tert-butoxide

[0275] MeOH: methanol

[0276] mL: milliliter

[0277] mmol: millimole

[0278] Na2SO4: sodium sulfate

[0279] NaOtBu: Sodium tert-butoxide, instruction manual 18 / 61, page 27, CN 122161829 A

[0280] ppm (parts per million)

[0281] Pd(dppf)Cl2: 1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride

[0282] Pd2(dba3): tris(dibenzylideneacetone)dipalladium

[0283] Ph3P: triphenylphosphine

[0284] RT: room temperature

[0285] THF: tetrahydrofuran

[0286] Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthanium

[0287] Examples

[0288] The compounds of the present invention were prepared using appropriate materials and conditions according to the following experimental procedures. The following examples are provided by way of illustration only and are not intended to limit the scope of the invention.

[0289] Preparation of intermediates:

[0290] Intermediate-1: 6-chloro-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine

[0291] Formylhydrazine (2 g, 33.90 mmol) was added to a stirred solution of 3,6-dichloro-4,5-dimethylpyridazine (2 g, 11.29 mmol) in 1-butanol (20 mL) at room temperature, and the reaction mixture was refluxed for 16 h. Volatiles were removed under reduced pressure, and the resulting solid was purified by silica gel column chromatography using 1%–2% MeOH in DCM to obtain the target compound. Yield: 1.2 g (60%); 1H-NMR (CDCl3, 400 MHz) δ ppm: 2.43 (s, 3H), 2.74 (s, 3H), 8.96 (s, 1H); mass (m / z): 183.0, 185.1 (M+H)+.

[0292] Intermediate-2: 6-chloro-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine

[0293] Formylhydrazine (1.8 g, 30.67 mmol) was added to a stirred solution of 3,6-dichloro-4-methylpyridazine (2.0 g, 12.26 mmol) in 1-butanol (30 mL) at room temperature, and the reaction mixture was refluxed for 16 h. Volatiles were removed under reduced pressure, and the resulting mixture of methyl regioisomers (1:1) was purified by column chromatography. The target compound was obtained using 60%–80% EtOAc in n-hexane. Yield: 0.3 g (18%); 1H-NMR (CDCl3, 400 MHz) δ ppm: 2.50 (s, 3H), 7.95 (s, 1H), 8.99 (s, 1H); mass (m / z): 168.6, 170.4 (M+H)+.

[0294] Intermediate-3: 6-chloro-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine

[0295] Intermediate-3 was obtained by using 3,6-dichloro-4,5-dimethylpyridazine and acetylhydrazine as starting materials and with some non-critical variations, following the procedure given for intermediate-1. 1H – NMR (CDCl3, 400 MHz) δ ppm: 2.41 (s, 3H), 2.71 (s, 3H), 2.77 (s, 3H); mass (m / z): 196.9, 198.8 (M+H)+.

[0296] Intermediate-4: 6-chloro-7,8-dimethyl-3-trifluoromethyl[1,2,4]triazolo[4,3b]pyridazine

[0297] Step 1: (6-chloro-4,5-dimethyl-pyridazine-3-yl)-hydrazine

[0298] Hydrazine hydrate (0.42 mL, 8.4 mmol) was added to a stirred solution of 3,6-dichloro-4,5-dimethyl-pyridazine (0.1 g, 5.6 mmol) in 1,4-dioxane (10 mL), and the reaction mixture was refluxed for 7 h, during which time a solid precipitated. These solids were filtered and dried under vacuum to obtain the target compound. Yield: 0.78 g (80%); Mass (m / z): 172.8, 174.8 (M+H)+

[0299] Step 2: 6-chloro-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine

[0300] A stirred suspension of (6-chloro-4,5-dimethyl-pyridazine-3-yl)-hydrazine (0.3 g, 1.7 mmol) in trifluoroacetic acid (0.71 mL, 8.7 mmol) was heated in a sealed tube at 120ºC for 2 h. Water (20 mL) was added to the reaction mixture and extracted with EtOAc (100 mL x 3). The combined organic layers were subjected to a saline solution (50 mL)The sample was washed (mL), dried over Na2SO4, and concentrated under reduced pressure to give the target compound. Yield: 0.19 g (44%); 1H – NMR (CDCl3, 400 MHz) δ ppm: 2.48 (s, 3H), 2.79 (s, 3H); mass (m / z): 250.7, 252.7 (M+H)+. Instructions 19 / 61 Page 28 CN 122161829 A

[0301] Intermediate-5: 6-chloro-3-difluoromethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine

[0302] Intermediate-5 was obtained by using (6-chloro-4,5-dimethyl-pyridazine-3-yl)-hydrazine (step 1 of intermediate-4) and difluoroacetic acid as starting materials and with some non-critical variations, following the procedure given for intermediate-4. 1H – NMR (CDCl3, 400 MHz) δ ppm: 2.47 (s, 3H), 2.77 (s, 3H), 7.07 – 7.33 (m, 1H); mass (m / z): 233.8, 235.7 (M+H)+.

[0303] Intermediate-6: 6-chloro-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine

[0304] Intermediate-6 was obtained by using 3,6-dichloro-4-methylpyridazine and acetylhydrazine as starting materials and with some non-critical variations, following the procedure given for intermediate-2. ¹H-NMR (CDCl3, 400 MHz) δ ppm: 2.47 (s, 3H), 2.79 (s, 3H), 7.87 (s, 1H); mass (m / z): 182.9, 184.8 (M+H)+.

[0305] Intermediate-7: 6-chloro-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine

[0306] Step 1: (6-chloro-5-methyl-pyridazine-3-yl)-hydrazine

[0307] Hydrazine hydrate (6.6 mL, 13.5 mmol) was added to a stirred solution of 3,6-dichloro-4-methyl-pyridazine (20 g, 12.3 mmol) in 1,4-dioxane (100 mL), and the reaction mixture was refluxed for 7 h, during which time a solid precipitated. These solids were filtered and dried under vacuum to obtain the target compound. Yield: 18.0 g (91%); mass (m / z): 158.8, 160.8 (M+H)+.

[0308] Step 2: 6-Chloro-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine

[0309] (6-chloro-5-methyl-pyridazine-3-yl)-hydrazine (4.0A stirred suspension of 2.5 mmol (g, 12.6 mmol) in trifluoroacetic acid (10.3 mL, 12.6 mmol) was heated at 120ºC for 4 h in a sealed tube. Water (20 mL) was added to the reaction mixture and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with a brine solution (50 mL), dried over Na2SO4, and concentrated under reduced pressure to give a mixture of methyl regioisomers (1:1). The target compound was obtained using 40% EtOAc in n-hexane. Yield: 1.8 g (30.5%); 1H-NMR (CDCl3, 400 MHz) δ ppm: 2.56 (s, 3H), 8.04 (s, 1H); mass (m / z): 236.8, 238.9 (M+H)+

[0310] Intermediate-8: 6-chloro-3-difluoromethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine

[0311] Intermediate-8 was obtained by using (6-chloro-5-methyl-pyridazine-3-yl)-hydrazine (step 1 of intermediate-7) and difluoroacetic acid as starting materials and with some non-critical variations, following the procedure given for intermediate-7. 1H-NMR (CDCl3, 400 MHz) δ ppm: 2.54 (s, 3H), 7.21 – 7.34 (m, 1H), 8.01 (s, 1H); mass (m / z): 218.6, 220.7 (M+H)+.

[0312] Intermediate-9: 6-chloro-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine

[0313] Intermediate-9 was obtained by using (6-chloro-4,5-dimethyl-pyridazine-3-yl)-hydrazine (step 1 of intermediate-4) and 2-methoxyacetyl chloride as starting materials and with some non-critical variations, following the procedure given for intermediate-4. ¹H-NMR (CDCl3, 400 MHz) δ ppm: 2.57 (s, 3H), 2.98 (s, 3H), 3.50 (s, 3H), 5.04 (s, 2H); mass (m / z): 226.8, 228.7 (M+H)+.

[0314] Intermediate-10: 6-chloro-3-methoxymethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine

[0315] Intermediate-10 was obtained by using (6-chloro-5-methyl-pyridazine-3-yl)-hydrazine (step 1 of intermediate-7) and 2-methoxyacetyl chloride as starting materials and with some non-critical variations, following the procedure given for intermediate-7. ¹H-NMR (CDCl₃, 400 MHz) δppm: 2.50 (s, 3H), 3.48 (s, 3H), 4.99 (s, 2H), 7.94 (s, 1H); mass (m / z): 213.1, 216.0 (M+H)+.

[0316] Intermediate-11: 6-chloro-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine

[0317] DMF-DMA (0.46 g, 4.14 mmol) was added to the stirred solution of 6-chloro-4,5-dimethyl-pyridazine-3-ylamine (0.5 g, 31.84 mmol) in 2-propanol (15 mL), and the mixture was heated at 90ºC for 3 h. The reaction mixture was then cooled to 55ºC–60ºC, and hydroxylamine hydrochloride (0.27 g, 4.14 mmol) was added, followed by further stirring at 55ºC–60ºC for 2 h. Volatiles were removed under reduced pressure, and polyphosphoric acid (5 g) was added at room temperature. The reaction mixture was further heated at 110ºC for 3 h. The reaction mixture was then cooled to room temperature, and ammonia was slowly added to the reaction mixture, during which solids precipitated. These solids were filtered and dried under reduced pressure to obtain the target compound. Yield: 0.5 g (32%); ¹H–NMR (CDCl₃, 400 MHz) δ ppm: 2.49 (s, 3H), 2.71 (s, 3H), 8.38 (s, 1H); mass (m / z): 182.9, 184.7 (M+H)+.

[0318] Intermediate-12: 6-chloro-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine

[0319] Intermediate-12 was obtained by using 6-chloro-5-methyl-pyridazine-3-ylamine and DMF-DMA as starting materials and employing some non-critical variations, following the procedure given for intermediate-11. 1H-NMR (CDCl3, 400 MHz) δ ppm: 2.47 (s, 3H), 7.52 (s, 1H), 7.87 (s, 1H); mass (m / z): 168.9, 170.8 (M+ H)+.

[0320] Intermediate-13: 6-chloro-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine

[0321] Intermediate-13 was obtained by using 6-chloro-4,5-dimethyl-pyridazine-3-ylamine and DMA-DMA as starting materials and with some non-critical variations, following the procedure given for intermediate-11. 1H-NMR (CDCl3, 400 MHz) δ ppm: 2.46(s, 3H) , 2.62 (s, 3H) , 2.66 (s, 3H); mass (m / z): 196.9, 198.8 (M+H)+.

[0322] Intermediate-14: 6-chloro-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine

[0323] Intermediate-14 was obtained by using 6-chloro-5-methylpyridazine-3-ylamine and DMA-DMA as starting materials and with some non-critical variations, following the procedure given for intermediate-11. 1H-NMR (CDCl3, 400 MHz) δ ppm: 2.52 (s, 3H), 2.63 (s, 3H), 7.82 (s, 1H); mass (m / z): 182.9, 184.8 (M+H)+.

[0324] Intermediate-15: 6-chloro-2,7-dimethyl-imidazo[1,2-b]pyridazine

[0325] Chloroacetone (2 g, 10.65 mmol) was added to a stirred solution of 6-chloro-5-methylpyridazine-3-ylamine (0.42 g, 2.60 mmol) in 1-butanol (10 mL) at room temperature, and the reaction mixture was refluxed for 8 h. Volatiles were removed under reduced pressure, and the resulting solid was purified by silica gel column chromatography using 1%–2% MeOH in DCM to obtain the target compound. Yield: 0.15 g (38%); 1H – NMR (CDCl3, 400 MHz) δ ppm: 2.43 (s, 3H), 2.47 (s, 3H), 7.64 (m, 2H); mass (m / z): 181.7, 182.8 (M+H)+.

[0326] Intermediate-16: 6-chloro-2,7,8-trimethyl-imidazo[1,2-b]pyridazine

[0327] Intermediate-16 was obtained by using 6-chloro-4,5-dimethyl-pyridazine-3-ylamine and chloroacetone as starting materials and employing some non-critical variations, following the procedure given for intermediate-15. 1H – NMR (CDCl3, 400 MHz) δ ppm: 2.38 (s, 3H), 2.47 (s, 3H), 2.63 (s, 3H), 7.59 (s, 1H); mass (m / z): 196.0, 197.8 (M+H)+

[0328] Intermediate-17: 6-chloro-2-fluoromethyl-7,8-dimethyl-imidazo[1,2-b]pyridazine

[0329] Add 1,3-difluoroacetone (0.5 mL, 6.3 mmol) to a stirred solution of 6-chloro-4,5-dimethylpyridazine-3-ylamine (0.5 g, 3.1 mmol) in ethanol (20 mL) at room temperature.The reaction mixture was refluxed for 16 h. Volatiles were removed under reduced pressure, and the resulting solid was purified by silica gel column chromatography using 30%–40% EtOAc in n-hexane to obtain the target compound. Yield: 0.25 g (36.8%); 1H-NMR (DMSO-d6, 400 MHz) δ ppm: 2.36 (s, 3H), 2.59 (s, 3H), 5.43 (s, 1H), 5.55 (s, 1H), 8.36 (s, 1H); Mass (m / z): 213.8, 215.8 (M+H)+

[0330] Intermediate-18: 6-chloro-2-fluoromethyl-7-methyl-imidazo[1,2-b]pyridazine

[0331] Intermediate-18 was obtained by using 6-chloro-5-methylpyridazin-3-ylamine and 1,3-difluoroacetone as starting materials and employing some non-critical variations, following the procedure given for intermediate-17. ¹H-NMR (DMSO-d6, 400 MHz) δ ppm: 2.38 (s, 3H), 5.43 (s, 1H), 5.55 (s, 1H), 7.96 (s, 1H), 8.36 (s, 1H); mass (m / z): 199.8, 201.7 (M+H)+

[0332] Intermediate-19: 6-chloro-2,3,7-trimethyl-imidazo[1,2-b]pyridazine

[0333] At room temperature, 6-chloro-5-methylpyridazin-3-ylamine (0.3 g, 2.08 g, 1,3-difluoroacetone) was used as the starting material. 3-Bromo-2-butanone (0.6 g, 2.49 mmol) was added to a stirred solution of ethanol (10 mL), and the reaction mixture was refluxed for 16 h. Volatiles were removed under reduced pressure, and the resulting solid was purified by silica gel column chromatography using 1%–2% MeOH in DCM to obtain the target compound. Yield: 0.2 g (75%); ¹H–NMR (CDCl₃, 400 MHz) δ ppm: 2.42 (s, 3H), 2.43 (s, 3H), 2.47 (s, 3H), 7.63 (m, 1H); mass (m / z): 196.0, 197.8 (M+H)+.

[0334] Intermediate-20: 2,6-dichloro-7,8-dimethyl-imidazo[1,2-b]pyridazine

[0335] Chloroacetic acid (0.43 g, 63.0 mmol) and triethylamine (0.6 mL, 4.90 mmol) were added sequentially at room temperature to...6-Chloro-4,5-dimethyl-pyridazine-3-ylamine (0.77 g, 4.90 mmol) was in a stirred solution of ethanol:water (1:1 mL). The reaction mixture was heated at 110ºC for 10–12 h, followed by cooling to room temperature. Water (50 mL) was added to the reaction mixture and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with a saline solution (100 mL), dried over Na2SO4, and concentrated under reduced pressure to give the crude compound, which was purified by silica gel column chromatography using 2%–4% MeOH in DCM to give the target compound. Yield: 0.34 g (38%); mass (m / z): 217.2, 219.5 (M+H)+.

[0336] Intermediate-21: 6-chloro-7-methyl-imidazo[1,2-b]pyridazine

[0337] Chloroacetaldehyde (2 g, 10.65 mmol) was added to a stirred solution of 6-chloro-5-methyl-pyridazine-3-ylamine (0.42 g, 2.60 mmol) in 1-butanol (10 mL) at room temperature, and the reaction mixture was refluxed for 16 h. Volatiles were removed under reduced pressure, and the resulting solid was purified by silica gel column chromatography using 1%–2% MeOH in DCM to obtain the target compound. Yield: 0.4 (88%); ¹H-NMR (CDCl₃, 400 MHz) δ ppm: 2.45 (s, 3H), 7.71 (s, 1H), 7.77 (s, 1H), 7.87 (s, 1H); mass (m / z): 167.6, 170.0 (M+H)+.

[0338] Intermediate-22: 6-chloro-7,8-dimethyl-imidazo[1,2-b]pyridazine

[0339] Intermediate-22 was obtained by using 6-chloro-4,5-dimethyl-pyridazine-3-ylamine and chloroacetaldehyde as starting materials and with some non-critical variations, following the procedure given for intermediate-21. 1H-NMR (CDCl3, 400 MHz) δ ppm: 2.44 (s, 3H), 2.67 (s, 3H), 8.17 (s, 1H), 8.52 (s, 1H); mass (m / z): 181.8, 184.2 (M+H)+.

[0340] Intermediate-23: 4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidine hydrochloride

[0341] Step 1: 4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidine-1-carboxylate tert-butyl ester

[0342] At room temperature, tert-butyl 4-hydroxy-piperidine-1-carboxylate (15.86 g, 78.94 g) was added to tert-butyl 4-hydroxy-piperidine-1-carboxylate (78.94 g).2,3-Dihydro-benzo[1,4]dioxin-6-ol (12 g, 78.94 mmol) and Ph3P (25 g, 94.73 mmol) were sequentially added to a stirred solution of THF aqueous solution (120 mL). The mixture was cooled to 0–5ºC, DIAD (32 g, 157.8 mmol) was added, and the reaction mixture was brought to room temperature and stirred further at room temperature for 16 h. Volatiles were removed under reduced pressure, and the resulting residue was purified by silica gel column chromatography using 10%–12% EtOAc in n-hexane to obtain the target compound. Yield: 12.6 g (48%); ¹H-NMR (CDCl₃, 400 MHz) δ ppm: 1.42 – 1.46 (s, 9H), 1.69 – 1.72 (m, 2H), 1.85 – 1.87 (m, 2H), 3.25 – 3.31 (m, 2H), 3.66 – 3.72 (m, 2H), 4.20 – 4.23 (m, 4H), 4.24 – 4.31 (m, 1H), 6.41 – 6.46 (m, 2H), 6.74 – 6.77 (d) (See instruction manual, pages 22 / 61, CN 122161829 A) , J = 8.8 Hz, 1H); mass (m / z): 336.2 (M+H)+.

[0343] Step 2: 4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidine hydrochloride

[0344] IPA.HCl (30 mL, 10 vol., 12% w / v solution) was added to a stirred solution of 4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidine-1-carboxylic acid tert-butyl ester (12.6 g, 37.61 mmol) in MeOH (10 mL), and the reaction mixture was maintained at room temperature for 4 h. The volatiles were removed under reduced pressure to obtain the target compound. Yield: 9.2 g (90%); ¹H-NMR (DMSO-d6, 400 MHz) δ ppm: 1.74 – 1.77 (m, 2H), 2.01 – 2.06 (m, 2H), 3.01 – 3.02 (m, 2H), 3.17 (m, 2H), 4.16 – 4.20 (m, 4H), 4.46 – 4.49 (m, 1H), 6.45 – 6.46 (m, 1H), 6.54 – 6.55 (d, J = 2.8 Hz, 1H), 6.75 – 6.77 (d, J = 2.8 Hz, 1H).J = 8.8 Hz, 1H), 8.87 (bs, 2H); mass (m / z): 236.0 (M+H)+.

[0345] The following intermediates 24 to 35 were prepared using suitable starting materials given in the table below, by following the experimental procedures given in steps 1 and 2 of intermediate-23 and by adopting some non-critical variations.

[0346] Specification 23 / 61 pages 32 CN 122161829 A

[0347] Specification 24 / 61 pages 33 CN 122161829 A

[0348]

[0349] Method-I

[0350] Example-1: 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl- Specification 25 / 61 pages 34 CN 122161829 A [1,2,4]triazolo[4,3-b]pyridazine

[0351]

[0352] Cesium fluoride (1.4 g, 9.43 mmol), triethylamine (1.8 mL, 12.58 mmol) were added at room temperature. 0.85 g (3.14 mmol, intermediate-23) and 6-chloro-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine (0.53 g, 3.14 mmol, intermediate-2) were sequentially added to a stirred solution of 4-(2,3-dihydro-benzo[1,2,4]dioxin-6-yloxy)piperidine hydrochloride in DMSO (15 mL). The reaction mixture was heated at 110ºC for 10–12 h, followed by cooling to room temperature. Water (50 mL) was added to the reaction mixture and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with a saline solution (100 mL), dried over Na2SO4, and concentrated under reduced pressure to give the crude compound, which was purified by silica gel column chromatography using 2%–4% MeOH in DCM to obtain the target compound. Yield: 0.54 g (50%); 1H – NMR (CDCl3, 400 MHz) δ ppm: 1.92 – 1.99 (m, 2H), 2.08 – 2.13 (m, 2H), 2.40 (s, 3H), 3.08 – 3.13 (m, 2H), 3.43 – 3.49 (m , 2H) , 4.21 – 4.25 (m , 4H) , 4.37 – 4.41 (m , 1H) , 6.45 – 6.48 (m , 1H) , 6.50 – 6.51 (d , J = 2.4 Hz, 1H) , 6.77 – 6.79 (d , J = 8.4 Hz, 1H), 7.74(s, 1H), 8.83 (s, 1H); mass (m / z): 368.0 (M+H)+.

[0353] Method-II

[0354] Example-2: 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine

[0355]

[0356] Pd2dba3 (0.02 g, 0.02 mmol), BINAP (0.013 g, 0.02 mmol), followed by NaOtBu (0.84 g, 0.8 mmol) were sequentially added to 4-(2,3-dihydro-benzofuran-6-yloxy)-piperidine hydrochloride (0.05 g, 0.2 mmol, intermediate-25) and 6-chloro-7,8-dimethyl-imidazo[1,2-b]pyridazine (0.04 g, 0.2 mmol) at room temperature. mmol (intermediate-22) was added to toluene (20 mL) in a stirred solution. The reaction mixture was then refluxed under N2 atmosphere for 16 h. The reaction mixture was cooled to room temperature and poured into water (30 mL). The product was extracted with EtOAc (100 mL x 3). The organic extracts were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue, which was purified by column chromatography using 2%–4% MeOH in DCM to obtain the target compound. Yield: 0.05 g (62.5%); 1H – NMR (CDCl3, 400 MHz) δ ppm: 1.92 – 1.98 (m, 2H), 2.08 – 2.13 (m, 2H), 2.28 (s, 3H), 2.28 (s, 3H), 2.95 – 3.02 (m, 2H) , 3.17 – 3.21 (t, J = 8.8Hz, 2H) , 3.35 – 3.41 (m ,2H) , 4.31– 4.33 (m , 1H) , 4.53 – 4.57 (t, J = 8.4 Hz, 2H) , 6.82 – 6.71 (m, 2H) , 6.85 – 6.85 (d, J = 1.2 Hz, 1H), 7.53 – 7.54 (d, J = 1.2 Hz, 1H), 7.69 – 7.69 (d, J = 1.2 Hz, 1H); mass (m / z): 365.2 (M+H)+.

[0357] Examples 3 to 126 were prepared using suitable intermediates (synthesized above) and with some non-critical variations, following the experimental procedures provided in Examples 1 or 2. DescriptionBook 26 / 61 pages 35 CN 122161829 A

[0358] Specification 27 / 61 pages 36 CN 122161829 A

[0359] Specification 28 / 61 pages 37 CN 122161829 A

[0360] Specification 29 / 61 pages 38 CN 122161829 A

[0361] Specification 30 / 61 pages 39 CN 122161829 A

[0362] Specification 31 / 61 pages 40 CN 122161829 A

[0363] Specification 32 / 61 pages 41 CN 122161829 A

[0364] Specification 33 / 61 pages 42 CN 122161829 A

[0365] Specification 34 / 61 pages 43 CN 122161829 A

[0366] Specification 35 / 61 pages 44 CN 122161829 A

[0367] Specification 36 / 61 pages 45 CN 122161829 A

[0368] Specification 37 / 61 pages 46 CN 122161829 A

[0369] Specification 38 / 61 pages 47 CN 122161829 A

[0370] Specification 39 / 61 pages 48 CN 122161829 A

[0371] Specification 40 / 61 pages 49 CN 122161829 A

[0372] Specification 41 / 61 pages 50 CN 122161829 A

[0373] Specification 42 / 61 pages 51 CN 122161829 A

[0374] Specification 43 / 61 pages 52 CN 122161829 A

[0375] Specification 44 / 61 pages 53 CN 122161829 A

[0376] Specification 45 / 61 pages 54 CN 122161829 A

[0377] Specification 46 / 61 pages 55 CN 122161829 A

[0378] Specification 47 / 61 pages 56 CN 122161829 A

[0379] Specification 48 / 61 pages 57 CN 122161829 A

[0380] Specification 49 / 61 pages 58 CN 122161829 A

[0381] Specification 50 / 61 pages 59 CN 122161829 A

[0382] Specification 51 / 61 pages 60 CN 122161829A

[0383] Specification 52 / 61 pages 61 CN 122161829 A

[0384] Specification 53 / 61 pages 62 CN 122161829 A

[0385] Specification 54 / 61 pages 63 CN 122161829 A

[0386]

[0387] Example 127: Determination of the allosteric power EC50 value of muscarinic M4 receptor

[0388] The ability of the compound to activate the muscarinic M4 receptor was tested. The experimental procedures and results are provided below.

[0389] A. CRE-Luc reporter assay - The CHO-K1 cell line (Chinese hamster ovary (CHO) K1 (ATCC CCL-61) purchased from ATCC) engineered to stably express the recombinant human muscarinic M4 receptor and pCRE-Luc reporter system was used for cell-based assays. The assays provide a non-radioactive method for determining the binding of the compound to the GPCR. In this specific assay, the level of intracellular cyclic AMP, regulated by receptor activation or inhibition, was measured. The recombinant cells contained a luciferase reporter gene controlled by the cyclic AMP response element.

[0390] The cells were grown in 96-well clear-bottom white plates in Hams F12 medium containing 10% fetal bovine serum (FBS, Thermo Fisher Scientific). The cells were serum-starved overnight before the addition of the compound or standard agonist. Incremental concentrations of the test compound were added to the cells along with acetylcholine and trichodin (1 µM) in EC20 of Opti-MEM medium.

[0391] Incubation was continued at 37ºC in a CO2 incubator for 4 h. After removing the medium, the cells were lysed with lysis buffer, the assay reagent was added, and luciferase activity was measured using a photometer. In the presence of tuftin (1 μM), the luciferase activity stimulated by the reference agonist (10 μM) was specified as 100%, while the basal luciferase activity (i.e., tuftin only (1 μM), in the absence of the reference agonist) was specified as 0%. After correction for the basal luciferase activity, the remaining luminescence values ​​of the compounds obtained at various doses were calculated according to the stimulated values ​​on pages 55 / 61, 64 CN 122161829 A of the specification. The relationship between compound activity (%) and compound concentration was plotted, and the dose-response curves were analyzed using a 4-parameter logistic fitting model of GraphPad Prism software. The EC50 value of the compound was defined as the concentration required to stimulate 50% luciferase activity in the presence of acetylcholine with EC20, and the results are provided as EC50 in Table 1A below.

[0392] Table 1A: Allosteric Power EC50 Values ​​of Muscarinic M4 Receptors

[0393]

[0394] B.Glosensor cAMP Assay – HEK293 cell lines (human embryonic kidney cells (HEK-293) (ATCC CRL-1573) purchased from ATCC) engineered to transiently express recombinant human muscarinic M4 receptor and pGloSensor-22F cAMP were used for the Glosensor cAMP assay. The assay provides a non-radioactive method for determining the binding of compounds to GPCRs. It utilizes a genetically encoded biosensor variant whose cAMP-binding domain is fused to a mutant form of firefly luciferase. Upon binding to cAMP, a conformational change occurs, resulting in a significant increase in light output. After pre-equilibration with the substrate, cells transiently or stably expressing the biosensor variant can be used to measure GPCR function using a live-cell, non-lytic assay, enabling easy measurement of the kinetics of cAMP accumulation or turnover in live cells.

[0395] The cells were grown overnight in a CO2 incubator at 37ºC in 96-well clear white plates in DuPont modified Eagle medium containing Glutamax and 10% fetal bovine serum (FBS, Thermo Fisher Scientific). Cells were pre-equilibrated with substrate for 2 h at room temperature in CO2-independent medium containing 10% FBS before adding the compound or standard agonist. Incremental concentrations of the test compound were added to the cells along with acetylcholine and isoproterenol (0.1 µM) of EC20 in CO2-independent medium containing 10% FBS.

[0396] Incubation was continued for 12 minutes at room temperature. After incubation, luciferase activity was measured using a photometer. In the presence of isoproterenol, the luciferase activity stimulated by a reference agonist (10 μM) was designated as 100%, while the basal luciferase activity (i.e., isoproterenol alone, in the absence of a reference agonist) was designated as 0%. After correction for basal luciferase activity, the remaining luminescence values ​​of the compounds obtained at various doses were calculated with reference to the stimulated values. The relationship between compound activity (%) and compound concentration was plotted, and the dose-response curves were analyzed using a 4-parameter logistic fitting model in GraphPad Prism software. The EC50 value of the compound was defined as the concentration required to stimulate 50% luciferase activity in the presence of acetylcholine with EC20, and the results are provided as EC50 in Table 1B below.

[0397] Table 1B: Allosteric Power EC50 Values ​​of Muscarinic M4 Receptors Specification 57 / 61 pages 66 CN 122161829 A

[0398]

[0399] C. Muscarinic M2CRE-Luc reporter assay – The CHO-K1 cell line (Chinese hamster ovary (CHO)K1 (ATCC CCL-61) purchased from ATCC) engineered to stably express the recombinant human muscarinic M2 receptor and pCRE-Luc reporter system was used for a cell-based assay. The assay provides a non-radioactive method to determine the binding of a compound to a GPCR. In this particular assay, the level of intracellular cyclic AMP, regulated by the activation or inhibition of the receptor, was measured. The recombinant cells contained a luciferase reporter gene controlled by the cyclic AMP response element.

[0400] The cells were grown in 96-well clear white plates in Hams F12 medium containing 10% fetal bovine serum (FBS purchased from Thermo Fisher Scientific). The cells were serum starved overnight before the addition of the compound or standard agonist. The test compound was added to the cells in progressively increasing concentrations along with acetylcholine and trichodin (1 M) in EC20 of Opti-MEM medium.

[0401] Cells were incubated for another 4 h at 37ºC in a CO2 incubator. After removing the culture medium, cells were lysed using lysis buffer, detection reagents were added, and luciferase activity was measured in a photometer. Luciferase activity stimulated with a reference agonist (10 μM) in the presence of tuftin (1 μM) was designated as 100%, while basal luciferase activity (i.e., tuftin only (1 μM), in the absence of a reference agonist) was designated as 0%. After correction for basal luciferase activity, the remaining luminescence values ​​of the compounds obtained at various doses were calculated with reference to the stimulated values. The relationship between compound activity (%) and compound concentration was plotted, and the dose-response curves were analyzed using a 4-parameter logistic fitting model in GraphPad Prism software. The EC50 value of compound A, page 58 / 61 of the specification, CN 122161829 A, is defined as the concentration required to stimulate 50% luciferase activity in the presence of acetylcholine with EC20, and the results are provided as EC50 in Table 1C below.

[0402] Table 1C: Allosteric Power EC50 Values ​​of Muscarinic M2 Receptors

[0403]

[0404] Example 128: Rodent Pharmacokinetic Study

[0405] Male Wistar rats (250 ± 50 g) were used as experimental animals. The animals were housed individually in polypropylene cages. Two days prior to the study, male Wistar rats were anesthetized with isoflurane for surgical placement of a jugular vein catheter. The test compound was administered to the rats at a dose of 5 mg / kg and a dose volume of 2 mL / kg. The rats were given food and water at will during acclimatization, surgical recovery, and the study.

[0406] Using 5% v / v DMSO + 5% v / v Solutol HS15 + 90%Preparations for intraperitoneal administration were prepared using v / v water for injection as the medium. Dosage preparations were freshly prepared on the day of administration.

[0407] Following administration, 200 µL of blood was collected via the jugular vein at each time point, and an equal volume of physiological saline was added. The collected blood samples were transferred to labeled eppendorf tubes containing 10 μL of heparin sodium (1000 IU / mL) as an anticoagulant. Blood samples were collected at 0.08, 0.25, 0.5, 1, 2, 3, 5, 7, and 24 h post-administration. The blood was centrifuged at 4,000 rpm for 10 min. Plasma was separated and stored frozen at -80ºC until analysis. The concentration of the test compound in the plasma was quantified using a qualified LC-MS / MS method with appropriate extraction techniques. The study samples were analyzed using calibration samples from the batch and quality control samples distributed throughout the batch.

[0408] Pharmacokinetic parameters Cmax, Tmax, AUC0-t, and t1 / 2 were calculated using a standard non-compartmental model with the Phoenix WinNonlin 8.1 software package. The pharmacokinetic characteristics of the test compounds are given in Table 2 below:

[0409] Table 2: Pharmacokinetic characteristics of the compounds of the present invention 59 / 61 pages 68 CN 122161829 A

[0410]

[0411] Example 129: Antagonism against amphetamine-induced hypermotility

[0412] Male Wistar rats weighing 230-250 g were used. The weight of the rats was recorded. The rats were randomly grouped according to their weight. The animals were brought to the laboratory 1 h before acclimatization to the laboratory conditions. The outdoor area was a 51 x 51 x 51 cm black arena surrounded by black plastic walls of the same size. The rats were acclimatized to the outdoor arena for a period of 30 minutes. The animals were given the appropriate treatment (mediator or test compound) based on brain exposure. After the acclimatization period, the animals were stimulated with amphetamine (0.5 mg / kg, subcutaneously) or the mediator. The animals were then placed in an open arena and the distance traveled by the rats was tracked using Videomot software for 120 minutes. The data were analyzed using GraphPad Prism. The results of the test compounds are given in Table 3 below:

[0413] Table 3: Antipsychotic drug-like activity of the compounds of the present invention

[0414]

[0415] Example-130: Receptor occupancy study in rats

[0416] Male Wistar rats (250 ± 50 g) were used as experimental animals. The animals were housed alone in polypropylene cages and acclimatized to the experimental conditions for 4 days. On the day of the experiment, the mediator (10 mL / kg) or the test compound (3, 10 or 30 g) was administered intraperitoneally to the rats.At the test compound's Tmax, 3 µg / kg MK-6884 (tracer) was administered intravenously to all rats via the lateral tail vein. Five minutes after tracer administration, rats were euthanized by cervical dislocation, the brain was isolated from the skull, sprayed with ice-cold water, and two brain regions (striatum and cerebellum) were separated and transferred to corresponding pre-labeled / weighed microcentrifuge tubes, stored on dry ice or at -80ºC until processing for tracer extraction and analysis (using LC-MS / MS-based methods). The tracer concentration in the study samples was analyzed using calibration samples from the batch and quality control samples distributed throughout the batch. Receptor occupancy in the striatum was calculated using a ratio method.

[0417] Table 4: Receptor Occupancy Rate of Test Compounds of the Invention, Page 60 / 61, 69 CN 122161829 A

[0418]

[0419] Example-131: Situational Fear Conditioning Memory

[0420] A rodent fear conditioning chamber (L x W x H, rat: 26 x 30 x 33 cm, Coulburn Instruments, USA) was used, placed in an anechoic chamber. A stainless steel grid floor (L x W, rat: 26 x 30 cm) connected to an impact scrambler was used to transmit the impact. A ventilation fan provided 60 dB of background noise. A bulb (fixed to the right wall, 27 cm above the chamber floor) provided ambient lighting. The experiment was recorded using a camera mounted on the ceiling of the cabinet, and the images were analyzed using freeze frame 3 software (V3.2.1). The fear conditioning chamber had a transparent acrylic panel.

[0421] On day 0, rats were randomly grouped according to their weight, with two rats housed in each cage.

[0422] On Day 1, rats were brought to the laboratory at least 1 hour before the experiment. Rats were acclimatized to the fear-conditioned compartment for 2 minutes. After acclimatization, rats received an unavoidable foot shock (unconditioned stimulus (US): 0.7 mA shock for 3 seconds). The shocks were repeated to deliver a total of eight USs after a 79-second interval between each administration. One minute after the last US, the animal was transferred to a home cage. The compartment was cleaned with 70% ethanol between tests. The test treatment was administered before the conditioned phase based on Tmax. Amphetamine 2 mg / kg was subcutaneously injected 25 minutes before the conditioned phase.

[0423] On Day 2, rats were brought to the laboratory at least 1 hour before the experiment. Freezing behavior was recorded for 733 seconds (starting from the time the animal was placed in the fear-conditioned compartment). After the 733-second behavior recording, the animal was transferred to a home cage. The duration of freezing was recorded (approximately 3 seconds or more without movement was rated as freezing behavior). For analysis...In the motion index, the freeze threshold was set to 10. The compartment was cleaned with 70% ethanol between tests.

[0424] Table 5: Cognitive-promoting activity of the compounds of the present invention

[0425] Specification 61 / 61 pages 70 CN 122161829 A

Claims

1. A compound of formula (I) Or its isotopic form, stereoisomer, or pharmaceutically acceptable salt. in, Each can be a single bond or a double bond independently; X1, X2, X3, and X4 are independently selected from N or C; provided that R2, R3, R4, or R5 does not exist when X1, X2, X3, or X4 is N. R1 is selected from halogen, cyano, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -C1-C4 alkoxyalkyl, -OC1-C4 alkyl or -OC1-C4 haloalkyl; When present, R2 is selected from hydrogen, deuterium, halogen, cyano, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl or -C1-C4 alkoxyalkyl; When present, R3 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl or -C1-C4 alkoxyalkyl; When present, R4 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl or -C1-C4 alkoxyalkyl; When present, R5 is selected from hydrogen, deuterium, halogen, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl or -C1-C4 alkoxyalkyl. When present, R6 is selected from hydrogen, deuterium, halogen, cyano, -OH, -CH2OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl or -C1-C4 alkoxyalkyl. R7 is " "Indicates an attachment point; R8 and R9 are independently hydrogen, halogen, cyano, -OH, -NH2, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, -OC1-C4 alkoxyalkyl, -NHC1-C4 alkyl; or alternatively, R8 and R9 together with the carbon atoms to which they are attached form a 5-8 membered heterocycle, wherein the heterocycle is optionally substituted by one to five substituents independently selected from hydrogen, oxo, deuterium, halogen, cyano, -OH, -C1-C4 alkyl, -C1-C4 haloalkyl, -C3-C7 cycloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, or -C1-C4 alkoxyalkyl; and m can be 0, 1, or 2.

2. A compound of formula (I) according to the foregoing embodiments, or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, wherein the compound is selected from: 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-[1-(7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-piperidin-4-yloxy]benzylnitrile; 6-[4-(2,5-difluoro-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-fluoro-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-fluoro-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 7-Methyl-6-[4-(6-methylpyridin-3-yloxy)piperidin-1-yl]-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-[1-(7-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-piperidin-4-yloxy]benzylnitrile; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-[1-(3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-piperidin-4-yloxy]benzylnitrile; 6-[4-(2-methoxy-pyridin-4-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[3-fluoro-4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-3,7,8-trimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-[1-(3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-piperidin-4-yloxy]benzylnitrile; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2-methoxy-pyridin-4-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-3,7-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-[1-(3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-piperidin-4-yloxy]benzylnitrile; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Methoxymethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-3-methoxymethyl-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-3-methoxymethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Methoxymethyl-6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-3-methoxymethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-3-methoxymethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-3-methoxymethyl-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(6-methoxy-pyridin-3-yloxy)piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 3-Difluoromethyl-6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2-methoxy-pyridin-4-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 3-[1-(2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazin-6-yl)-piperidin-4-yloxy]benzylnitrile; 6-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-2,7-dimethyl-[1,2,4]triazolo[1,5-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,7-dimethyl-imidazo[1,2-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,7,8-trimethyl-imidazo[1,2-b]pyridazine; 6-[4-(3-fluoro-phenoxy)-piperidin-1-yl]-2,7,8-trimethyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2-fluoromethyl-7,8-dimethyl-imidazo[1,2-b]pyridazine; 2-Fluoromethyl-6-[4-(6-methoxy-pyridin-3-yloxy)piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 2-Fluoromethyl-6-[4-(2-methoxy-pyridin-4-yloxy)piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2-fluoromethyl-7-methyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-2,3,7-trimethyl-imidazo[1,2-b]pyridazine; 2-Chloro-6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 2-Chloro-6-[4-(6-methoxy-pyridin-3-yloxy)piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-5-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine; 6-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7-methyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 6-[4-(6-methoxy-pyridin-3-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; 6-[4-(2,3-dihydro-benzofuran-6-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine; or 6-[4-(1,3-dihydro-isobenzofuran-5-yloxy)-piperidin-1-yl]-7,8-dimethyl-imidazo[1,2-b]pyridazine.

3. The compound of formula (I) according to claim 1 or claim 2, or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, is used as a positive allosteric modulator of muscarinic M4 receptor (M4 PAM).

4. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or claim 2, or an isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is used to treat a disease or disorder mediated by a muscarinic M4 receptor, wherein the disease or disorder is selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders.

6. A compound of formula (I) according to claim 1 or claim 2, or an isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, for the treatment of a disease or disorder mediated by a muscarinic M4 receptor, wherein the disease or disorder is selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders.

7. The compound for the use according to claim 6, wherein the mental disorder is selected from anxiety, personality disorder, depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), bipolar disorder, attention deficit / hyperactivity disorder (ADHD), psychosis, schizophrenia, substance use disorder, and other mental disorders.

8. The compound for the use according to claim 6, wherein the neurological disease or disorder is selected from Alzheimer's disease, Rett syndrome, Huntington's disease, vascular dementia, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

9. The compound for the use according to claim 6, wherein the cognitive impairment is selected from amnesia, dementia, forgetfulness, dementia caused by Alzheimer's disease, dementia caused by HIV disease, dementia caused by Huntington's disease, dementia caused by Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia, senile dementia, dementia associated with Down syndrome, dementia associated with Tourette syndrome, dementia associated with postmenopausal syndrome, Creutzfeldt-Jakob disease dementia, substance-induced persistent dementia, Pick's disease dementia, Huntington's disease dementia, traumatic brain injury, prions, HIV-related neurocognitive impairment, mild cognitive impairment, and any other disease with cognitive symptoms.

10. The compound for the use according to claim 7, wherein the schizophrenia is selected from cognitive impairment, positive symptoms of schizophrenia, and / or negative symptoms of schizophrenia.

11. The compound for the use according to claim 7, wherein the mental disorder is selected from psychosis associated with Alzheimer's disease, psychosis associated with Parkinson's disease, psychotic depression, psychosis associated with stroke, psychosis associated with epilepsy, psychosis associated with multiple sclerosis, psychosis associated with traumatic brain injury, substance-induced persistent delirium, or any other disease with psychotic features.